Ironwood Pharmaceuticals Stock Total Debt
| IRWD Stock | USD 3.67 0.15 4.26% |
Ironwood Pharmaceuticals fundamentals help investors to digest information that contributes to Ironwood Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Ironwood Stock. The fundamental analysis module provides a way to measure Ironwood Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ironwood Pharmaceuticals stock.
The current year's Total Debt To Capitalization is expected to grow to 2.08. Ironwood | Total Debt |
Ironwood Pharmaceuticals Company Total Debt Analysis
Ironwood Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Ironwood Pharmaceuticals Total Debt | 715.54 M |
Most of Ironwood Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ironwood Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ironwood Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Ironwood Pharmaceuticals is extremely important. It helps to project a fair market value of Ironwood Stock properly, considering its historical fundamentals such as Total Debt. Since Ironwood Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ironwood Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ironwood Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Ironwood Total Debt Historical Pattern
Today, most investors in Ironwood Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ironwood Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ironwood Pharmaceuticals total debt as a starting point in their analysis.
Ironwood Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Ironwood Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Ironwood Pharmaceuticals has a Total Debt of 715.54 M. This is 73.99% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 86.54% higher than that of the company.
Ironwood Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ironwood Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ironwood Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ironwood Pharmaceuticals by comparing valuation metrics of similar companies.Ironwood Pharmaceuticals is currently under evaluation in total debt category among its peers.
Ironwood Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ironwood Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ironwood Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Ironwood Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Ironwood Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ironwood Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ironwood Pharmaceuticals' value.| Shares | Kynam Capital Management, Lp | 2024-09-30 | 3.7 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.9 M | Jpmorgan Chase & Co | 2024-06-30 | 1.9 M | Ubs Group Ag | 2024-06-30 | 1.8 M | Amvescap Plc. | 2024-06-30 | 1.7 M | Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Jupiter Asset Management Limited | 2024-09-30 | 1.4 M | Blackrock Inc | 2024-06-30 | 22.9 M | Vanguard Group Inc | 2024-09-30 | 22 M |
Ironwood Fundamentals
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 160.03 M | ||||
| Shares Owned By Insiders | 1.68 % | ||||
| Shares Owned By Institutions | 98.32 % | ||||
| Number Of Shares Shorted | 8.57 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 1.55 X | ||||
| Revenue | 442.74 M | ||||
| Gross Profit | 366.33 M | ||||
| EBITDA | (924.86 M) | ||||
| Net Income | (1 B) | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 715.54 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (1.95) X | ||||
| Cash Flow From Operations | 183.43 M | ||||
| Short Ratio | 6.44 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Price To Earnings To Growth | (0.26) X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 267 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 587.3 M | ||||
| Total Asset | 471.07 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | (42.81 M) | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
| Net Asset | 471.07 M |
About Ironwood Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ironwood Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ironwood Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ironwood Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out Ironwood Pharmaceuticals Piotroski F Score and Ironwood Pharmaceuticals Altman Z Score analysis. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.